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Abstract
Background: Streptococcus pneumoniae (pneumococcus) is responsible for over one million deaths
per year, with young children, the elderly and immunocompromised individuals being most at risk.
Approximately half of East African children have been reported to be asymptomatic carriers of
pneumococcus with invasive infection occurring after the disruption of the respiratory membrane
which is believed to be caused by the host immune response. Racial incidence of invasive
pneumococcal disease (IPD) is higher in certain populations even after adjusting for environmental
factors suggesting a genetic component to disease susceptibility. The nitric oxide synthase 2A
(NOS2A) gene is responsible for the production of nitric oxide under pathological conditions
including host defence against bacterial infection. Nitric oxide is a modulator of apoptotic and
inflammatory cascades and endothelial permeability. We hypothesised that genetic variants within
this gene may predispose to disease risk and survival.
Methods:  A cohort of 299 children with IPD (221 meningitis, 41 pneumonia and 37 with
bacteraemia) and 931 age matched controls from Malawi were used in this study. We investigated
nine haplotype tagging single nucleotide polymorphisms within the NOS2A gene and compared the
presence or absence of the minor alleles in cases and controls and survivors and non-survivors
within the cases.
Results: We observed no significant associations between cases and controls or with survival in
either all IPD cases or in the separate analysis of meningitis cases. A near significant association was
obtained for the comparison of rs8078340 in cases and controls (p-value, 0.078). However, results
were unadjusted for multiple testing.
Conclusion: Our results suggest that polymorphic variation within the NOS2A gene does not
influence invasive pneumococcal disease susceptibility or survival.
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Background
The pneumococcus is a principal contributor towards seri-
ous illness particularly in young children from developing
countries. It colonises the mucosal surface of the upper
respiratory tract and has been reported to have a nasopha-
ryngeal carriage of 57%, 41% and 6% in East African indi-
viduals aged 0–4, 5–9 and 10–85 years, respectively [1].
Invasive infection is achieved by the disruption of the res-
piratory epithelial membrane which is believed to be ini-
tiated by the host's immune response in a Toll-like
receptor 2 dependent manner [2,3]. This results in inva-
sive pneumococcal disease (IPD) which includes pneu-
monia, meningitis and bacteraemia. Meningitis has the
highest mortality rate (approximately 30%) with 21% of
meningitis survivors suffering neurological deficits which
include seizures, hearing loss and intellectual impairment
[4]. HIV positive individuals have a higher incidence of
disease with a reported 8.2 and 36.9-fold increase in
adults and children, respectively [5]. Other factors such as
overcrowding and exposure to smoke have also been asso-
ciated with increased prevalence of IPD [6]. Disease sever-
ity is dependent upon a number of factors including age,
co-morbid disease, pneumococcus strain, bacterial load
and pneumolysin allelic variation [7]. Our group have
shown that high blood and cerebral spinal fluid pneumo-
coccal DNA loads are associated with a fatal outcome in
Malawian children with IPD [8].
Certain racial groups including native American and Aus-
tralian populations and African Americans have a higher
incidence of IPD even after socio-economic factors have
been adjusted for suggesting that genetic variation may
predispose to disease development [9]. Current knowl-
edge of genetic variation and immune response to IPD is
limited although associations have been reported
between polymorphisms within six genes of members of
the family of inhibitors of nuclear factor (NF)-kappaB,
NFKBIA and NFKBIE [10], the adaptor protein Mal [3],
the Fc fragment of IgG, low affinity IIa, receptor (CD32)
[11], interleukin-10 [12], C-reactive protein [13] and
mannose-binding lectin (MBL) [14]. The only attempted
replication of these findings has been with CD32 and
MBL where subsequent investigations failed to find an
association [15,16].
Nitric oxide (NO) is a pleiotropic substance that has been
shown to regulate vascular permeability, motor control
and host defence against bacterial and parasitic infections
[17-19]. Under non-pathological conditions neuronal
and endothelial nitric oxide synthase (NOS1 and NOS3,
respectively) are responsible for NO production by cata-
lysing the breakdown of L-arginine into NO and L-citrul-
line. Whilst, NOS1 and NOS3 are involved in the immune
response, another isoform of NOS called inducible NOS
(NOS2) is responsible for a much greater expression of
NO in response to injury or infection [20]. NO is pro-
duced by the majority of immune response cells including
alveolar macrophages which are the first cells involved in
phagocytosis and early proinflammatory cytokine release
during respiratory infection [21]. Successful phagocytosis
of pneumococcus by macrophages has been shown to
increase NOS2 and NO production [22]. This increase
results in down-regulation of anti-apoptotic proteins, up-
regulation of pro-apoptotic proteins, mitochondrial
membrane permeabilisation and ultimately apoptosis of
the macrophage. In the same study NOS2 inhibitors
reduced bacterial killing and shifted macrophage death
from apoptotic to necrotic. Apoptosis has been shown to
play an important role in neuronal cell death caused by
IPD and this process is believed to be responsible for the
high mortality in meningitis [23]. NOS2 has also been
shown to influence the inflammatory response to bacte-
rial lipopolysaccharide through the regulation of the
cytokine response [24]. Brain protein levels of IL-1β, IL-6,
TNF-α, MIP-1α, MIP-2 are reduced in inducible NOS
(iNOS) deficient, pneumococcal meningitis induced mice
suggesting that iNOS derived NO plays a role in cytokine
and chemokine upregulation [25]. This study also
reported that iNOS-derived NO plays a role in peroxyni-
trite formation which disrupts the blood brain barrier.
Finally, pneumolysin, a pore-forming hemolysin, and an
important pneumococcal virulence factor has been shown
to induce iNOS, and NO production in macrophages
[26].
Here we investigate the influence of haplotype tagging
SNPs (htSNPs) within the NOS2A gene (43.8 kb gene that
codes for NOS2; chromosome position 17q11.2), on
both disease susceptibility and survival in a cohort of chil-
dren with IPD and age matched controls from Malawi.
Methods
Study population
The 299 children with IPD (aged 2 months to 16 years)
recruited into this study were admitted from the Queen
Elizabeth Central Hospital, Blantyre, Southern Malawi.
HIV prevalence of paediatric inpatients in this area is 19%
with 34% prevalence reported in children with bacterial
meningitis [27,28]. Pneumococcal vaccine was not avail-
able and at time of admission only 2 participants were
receiving antiretroviral therapy and 3 were on co-trimoxa-
zole prophylaxis. Only children with confirmed IPD (by
culture, PCR, microscopy or latex antigen tests) were
included in the study. Pneumococcal pneumonia was
confirmed by radiology and positive blood or lung aspi-
rate by culture or PCR. Pneumococcal meningitis was con-
firmed by CSF cell count (>10 μl-1) and one of the
following tests: CSF culture, gram stain, polysaccharide
antigen and/or pneumococcal PCR positive. Of the 299
cases, 221 were diagnosed with meningitis, 41 with pneu-BMC Medical Genetics 2009, 10:28 http://www.biomedcentral.com/1471-2350/10/28
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monia and 37 with bacteraemia alone. Of the 41 cases
with pneumococcal pneumonia, 13 (32%) were bacterae-
mic by blood culture or PCR and 31 (78%) were positive
by PCR of lung aspirate. As the majority of patients with
pneumococcal pneumonia do not have bacteraemia, we
did not make this a requirement to fulfil the criteria of
invasive pneumococcal disease. The number of cases who
survived was 234 and the number who died was 65. The
931 controls consisted of age matched, afebrile and apar-
asitemic children from the same villages as the cases. HIV
status was determined by either Unigold (Trinity Biotech,
Wicklow, Ireland), Serocard (Trinity Biotech, Wicklow,
Ireland) or Determine-HIV (Abbott Diagnostics Ltd,
Maidenhead, U.K.) in children over 18 months and
Amplicor HIV-1 Test version 1.5 (Roche Diagnostics, Indi-
anapolis, U.S.A.) in those under 18 months. Further
details on laboratory methods and management proto-
cols can be found elsewhere [8]. Ethical approval was
obtained from both The College of Medicine Research
and Ethics Committee and the Liverpool School of Tropi-
cal Medicine Research and Ethics Committee.
Genotyping
NOS2A polymorphism information was obtained from
the HapMap http://www.hapmap.org Yoruba population
data. Haploview Version 4.1 was used to select htSNPs,
with an r2 threshold of 0.8 [29]. The htSNPs comprised:
rs8078340, rs2779248, rs16966563, rs3794763,
rs1137933, rs17718148, rs4796052, rs2297518,
rs2314809, rs2297512. PCR reactions were carried out on
PTC-225 Peltier Thermal Cyclers (MJ Research, Waltham,
USA) in 384 well microtitre plates using 10 ng of genomic
DNA with a final reaction volume of 10 μl. Primer details
and PCR conditions can be obtained from the corre-
sponding author. Five replication samples and two blank
controls were used as quality controls for each plate. Gen-
otyping was performed using Sequenom™ technology
(San Diego, USA). All laboratory work was performed
under the ISO 9001:2000 quality management require-
ments.
Analysis
Hardy-Weinberg equilibrium was calculated using
Golden Helixtree Genetics Analysis software version 5.0
(Golden Helix, Inc. MT, USA). The influence of genotype
on cases and controls and survival in cases was performed
in Stata v.8.2 (StataCorp, Texas, USA) using logistic regres-
sion analysis. The number of homozygous individuals for
the minor allele was small (<50) for the majority of geno-
types and they were pooled with heterozygous individu-
als. Analysis was therefore performed for the presence or
absence of the minor allele. Data were adjusted for bacte-
rial load, HIV status, disease type (pneumonia, meningitis
or bacteraemia), age and gender for the analysis of geno-
type and survival. HIV status was not available for the con-
trols and therefore case-control analysis was only adjusted
for age and gender. Survival analysis was performed on all
IPD cases and meningitis cases separately. Survival in
pneumonia and bacteraemia cases was not performed due
to the low number of deaths in each group (6 and 7,
respectively).
Results
Minor allele frequencies (MAF), Hardy-Weinberg equilib-
rium (HWE) p-values and successful genotype call rates
are given in Table 1. SNP rs2297518 had a low call rate
success (33%) and was excluded from analysis. MAF was
compared against that given on HapMap for the Nigerian
Yoruba in Ibadan (YRI) population. Five SNPs
(rs2779248, rs16966563, rs1137933, rs4796052 and
rs2297512) had similar frequencies (<3% difference).
SNPs rs8078340, rs3794763, rs17718148, and rs2314809
had frequencies of 0.24, 0.27, 0.16, and 0.38 in the
Malawi controls and 0.13, 0.11, 0.01, and 0.33 in the YRI
population, respectively. MAF of our cases and controls
were similar with the largest difference being 4%
(rs8068149).
Association analysis results are given in Table 2. We
observed no significant associations between cases and
controls or with survival in either all IPD cases or in the
Table 1: NOS2A htSNP gene position, minor allele frequencies (MAF), successful genotype call rates and Hardy-Weinberg equilibrium 
p-values (HWE P) in Malawi IPD cases and controls
Reference SNP Position Nucleotide substitution MAF case MAF control Call rate HWE P
rs8078340 5' near gene G>A 0.27 0.24 0.97 0.13
rs2779248 5' near gene T>C 0.46 0.45 0.99 0.70
rs16966563 Exon 4 Pro68Pro T>C 0.26 0.26 0.97 0.95
rs3794763 Intron 5 G>A 0.27 0.27 0.98 0.43
rs1137933 Exon 10 Asp385Asp C>T 0.14 0.17 0.97 0.85
rs17718148 Intron 11 C>T 0.13 0.16 0.98 0.45
rs4796052 Intron 11 C>T 0.20 0.21 0.98 0.83
rs2297518 Exon 16 Leu608Ser G>A 0.25 0.25 0.33 0.36
rs2314809 Intron 17 T>C 0.39 0.38 0.97 0.61
rs2297512 Intron 20 A>G 0.16 0.16 0.97 0.92BMC Medical Genetics 2009, 10:28 http://www.biomedcentral.com/1471-2350/10/28
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separate analysis of meningitis cases. A near significant
association was obtained for the comparison of
rs8078340 in cases and controls (p-value, 0.078). How-
ever, results were unadjusted for multiple testing and the
near significant association likely occurred by chance
given we performed 27 comparisons.
Discussion
We have investigated nine htSNPs that span the NOS2A
gene and found that they do not influence disease suscep-
tibility or survival in a Malawi IPD cohort. These results
suggest either NOS2A polymorphisms are not associated
with the disease or that the genetic effect size was too
small for our cohort of 299 cases and 931 controls to
detect. This sample size gives us 85% power to detect an
odds ratio of 1.5 for our cases and controls assuming a
minor allele frequency of 0.25 (average of our htSNPs)
and a significance level of 0.05. Subdividing our cases by
survival reduces power to 82% for detecting an odds ratio
of 2.4 using the same parameters. Given the high levels of
Table 2: Comparison of NOS2A htSNP allele frequencies between cases and controls and survival in cases
Reference SNP Homozygou wild-type Presence of minor allele p-value 95% confidence interval for coefficient
n (%) n (%) n (%) n (%)
Case-control
Cases Controls Cases Controls
rs8078340 172 (59) 485 (54) 122 (41) 412 (46) 0.078 -0.59, 0.03
rs2779248 260 (88) 797 (87) 37 (12) 121 (13) 0.431 -0.65, 0.28
rs16966563 203 (69) 634 (70) 90 (31) 270 (30) 0.714 -0.27, 0.39
rs3794763 193 (65) 575 (63) 102 (35) 337 (37) 0.331 -0.16, 0.48
rs1137933 183 (63) 580 (64) 109 (37) 326 (36) 0.908 -0.30, 0.34
rs17718148 212 (72) 677 (75) 81 (28) 229 (25) 0.718 -0.28, 0.40
rs4796052 201 (67) 673 (73) 97 (33) 240 (27) 0.106 -0.06, 0.59
rs2314809 158 (55) 485 (54) 131 (45) 415 (46) 0.956 -0.32, 0.30
rs2297512 157 (53) 496 (55) 138 (47) 407 (45) 0.913 -0.29, 0.32
Survival (all IPD cases)
Non-survivors Survivors Non-survivors Survivors
rs8078340 33 (51) 139 (61) 32 (49) 90 (39) 0.675 -1.09, 0.70
rs2779248 57 (88) 203 (88) 8 (12) 29 (12) 0.936 -1.14, 1.24
rs16966563 41 (63) 162 (71) 24 (37) 66 (29) 0.935 -0.90, 0.98
rs3794763 39 (60) 154 (67) 26 (40) 76 (33) 0.101 -0.16, 1.75
rs1137933 36 (56) 147 (64) 28 (44) 81 (36) 0.592 -0.68, 1.19
rs17718148 40 (62) 172 (74) 25 (38) 59 (26) 0.811 -1.11, 0.86
rs4796052 40 (62) 161 (69) 25 (38) 72 (31) 0.194 -1.54, 0.31
rs2314809 37 (58) 121 (54) 27 (42) 104 (46) 0.684 -0.72, 1.10
rs2297512 37 (57) 121 (52) 28 (43) 110 (48) 0.558 -0.64, 1.19
Survival (meningitis cases only)
Non-survivors Survivors Non-survivors Survivors
rs8078340 27 (47) 100 (62) 30 (53) 61 (38) 0.567 -1.20, 0.66
rs2779248 49 (86) 138 (85) 8 (14) 24 (15) 0.783 -1.37, 1.03
rs16966563 35 (61) 112 (70) 22 (39) 47 (30) 0.608 -0.93, 0.55
rs3794763 35 (61) 105 (65) 22 (39) 56 (35) 0.117 -0.20, 1.77
rs1137933 35 (63) 99 (62) 21 (37) 60 (38) 0.623 -0.72, 1.21
rs17718148 38 (67) 118 (73) 19 (33) 44 (27) 0.634 -1.25, 0.76
rs4796052 37 (65) 114 (70) 20 (35) 49 (30) 0.153 -1.66, 0.26
rs2314809 31 (55) 86 (54) 25 (45) 73 (46) 0.666 -0.75, 1.17
rs2297512 32 (56) 89 (55) 25 (44) 73 (45) 0.521 -0.64, 1.26
Data adjusted for age and sexBMC Medical Genetics 2009, 10:28 http://www.biomedcentral.com/1471-2350/10/28
Page 5 of 6
(page number not for citation purposes)
NO that are produced in response to pneumococcal infec-
tion it may be reasonable to assume that a genetic effect
would have to be large to impact on disease conversion or
severity. However, sample size is a limiting factor for this
study especially for the analysis of survival where we are
comparing 65 non-survivors against 234 survivors.
Associations between NOS2A polymorphisms and other
diseases have previously been reported. The exon 10 SNP
rs1137933 has been associated with Crohns disease and
the promoter SNP rs2779248 has been associated with
ulcerative colitis [30]. In addition, an exon 16 SNP
rs2297518 has been implicated in type-1 diabetes suscep-
tibility, risk of non-Hodgkin lymphoma and atrophic gas-
tritis [31-33]. Unfortunately, rs2297518 was excluded
from our analysis due to a low genotype success. This non-
synonymous SNP (Leu608Ser) cannot therefore be
excluded from association with IPD. The largest study of
NOS2A variation in multiple sclerosis demonstrated that
common variation within NOS2A alone does not appear
to significantly influence disease severity [34].
Conclusion
Whilst we cannot rule out that NOS2A influences disease
susceptibility or severity to IPD, our results suggest the
impact if any will be small. However, evidence from other
studies suggest that the immune response is important
both in the conversion of the asymptomatic carriage to
causing invasive disease and in the severity of the disease.
Other immune response genes should therefore be the
focus of future IPD genetic association studies.
Abbreviations
NOS2A: nitric oxide synthase 2A; IPD: invasive pneumo-
coccal disease; NO: Nitric oxide; iNOS: inducible nitric
oxide synthase.
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